Short Interest in AEterna Zentaris Inc. (AEZS) Drops By 29.7%
AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) was the target of a significant drop in short interest in the month of August. As of August 15th, there was short interest totalling 1,350,222 shares, a drop of 29.7% from the July 31st total of 1,920,407 shares. Currently, 13.7% of the company’s stock are short sold. Based on an average daily volume of 1,360,977 shares, the days-to-cover ratio is presently 1.0 days.
Shares of AEterna Zentaris (NASDAQ AEZS) opened at 1.97 on Tuesday. The firm’s market capitalization is $31.74 million. AEterna Zentaris has a 1-year low of $0.78 and a 1-year high of $5.59. The firm has a 50-day moving average of $1.81 and a 200-day moving average of $2.02.
AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by $0.05. The company had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.22 million. AEterna Zentaris had a negative net margin of 1,945.78% and a negative return on equity of 514.64%. The firm’s revenue for the quarter was up 153.1% compared to the same quarter last year. On average, equities research analysts anticipate that AEterna Zentaris will post ($1.02) EPS for the current fiscal year.
A number of research firms have issued reports on AEZS. Maxim Group lifted their target price on shares of AEterna Zentaris from $2.00 to $4.00 and gave the company a “buy” rating in a research note on Wednesday, July 19th. Zacks Investment Research upgraded shares of AEterna Zentaris from a “sell” rating to a “hold” rating in a research note on Tuesday, July 11th. Finally, HC Wainwright reduced their target price on shares of AEterna Zentaris from $7.50 to $3.00 and set a “buy” rating for the company in a research note on Wednesday, May 10th.
About AEterna Zentaris
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
Receive News & Stock Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related stocks with our FREE daily email newsletter.